Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Thursday 23 December, 2021

SkinBioTherapeutics

Result of AGM

RNS Number : 6628W
SkinBioTherapeutics PLC
23 December 2021
 

23 December 2021

 

SkinBioTherapeutics plc

 

 

Results of AGM

 

SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

 

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

 

Resolution

For & Discretionary

Against

Withheld

 

 

Number of votes

%

Number of votes

%

Number of votes

%

01

Ordinary resolution to receive and adopt the 2021 Financial Statements

46,333,616

 

100.00%

 

Nil

0.00%

1,138

0.002%

02

Ordinary resolution to re-appoint Jeffreys Henry as auditors

46,319,786

 

99.97%

 

13,830

0.03%

1,138

0.002%

03

Ordinary resolution to re-elect Stuart Ashman as a director

46,325,446

99.98%

738

0.002%

8,570

 

 

0.018%

04

Ordinary resolution to re-elect Martin Hunt as a director

46,272,446

99.87%

738

0.002%

61,570

 

 

0.133%

05

Ordinary resolution to re-elect Dr Cathy Prescott as a director

46,272,446

 

99.87%

 

53,738

0.116%

8,570

0.018%

06

Ordinary resolution to re-elect Doug Quinn as a director

46,272,446

99.87%

738

0.002%

61,570

0.133%

07

Ordinary resolution to authorise the directors to allot shares

46,210,124

99.73%

103,919

0.224%

20,711

0.045%

08

Special resolution to authorise the directors to disapply pre-emption rights

46,162,274

99.63%

151,769

0.328%

20,711

0.045%

09

Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment

46,190,229

99.69%

123,814

0.267%

20,711

0.045%

 

 

 

-Ends-

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis 

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis was launched on 29 October - World Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotix.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDKNBBBBDDPBB

a d v e r t i s e m e n t